Table 1. General characteristics of the study population.
| PsA (n = 40) | |
|---|---|
| Age, years | 50.3 ± 11.5 |
| Males, n (%) | 12 (30) |
|
PsA subset • Polyarthritis, n (%) • Oligoarthritis, n (%) • DIP predominant, n (%) • Spine predominant, n (%) • Arthritis mutilans, n (%) |
14 (35)12 (30)3 (7.5)11 (27.5)0 (0) |
| Enthesitis, n (%) | 8 (20) |
| Dactylitis, n (%) | 9 (22.5) |
| DAS28-CRP | 4.1 ± 0.9 |
| Disease duration, years | 3 (1.25–4.00) |
| Body Mass Index (BMI), kg/m2 | 30.8 ± 5.9 |
| sBP, mmHg | 128.4 ± 19.3 |
| dBP, mmHg | 80.7 ± 13.1 |
| BMI > 30 kg/m2, n (%) | 20 (50) |
|
Treatment • Methotrexate, n (%) • Sulfasalazine, n (%) • Cyclosporin A, n (%) • Infliximab, n (%) • Adalimumab, n (%) • Etanercept, n (%) • Golimumab, n (%) • Corticosteroids, n (%) |
23(32.5)2 (5)1 (2.5)2 (5)4 (10)3 (7.5)1 (2.5)9 (22.5) |
| ESR, mm/h | 18.2 ± 14.6 |
| hsCRP,mg/L | 5.5 ± 6.0 |
| C4, g/L | 0.26 ± 0.08 |
Legend: PsA, psoriatic arthritis; DIP, distal interphalangeal joint;DAS28-CRP, disease activity score including 28 joints and C-reactive protein; sBP, systolic blood pressure; dBP, diastolic blood pressure; BMI, body mass index; ESR, erythrocyte sedimentation rate; hsCRP, high-sensitivity C-reactive protein